Our CEO, Zachary Gobst, shared a few thoughts on the release of new guidance of Diversity Action Plans (DAPs) by the FDA. What are your thoughts on this new guidance? Share them in the comments below!
Great News in Clinical Trials! The FDA has just released new guidance on Diversity Action Plans (DAPs) aimed at improving the enrollment of underrepresented populations in clinical studies. This supports progress toward ensuring that clinical trials are more inclusive and reflective of our diverse society. At Leapcure, we are fully aligned with making a difference in this area. Our aim is to bring gravity to all voices and incorporate empathy with everyone—from patients and advocacy groups to research sites and sponsors—ensuring the most impactful medical breakthroughs. We look forward to collaborating with industry partners and the FDA to improve clinical trials. Together, we can lead the movement towards more inclusive, effective, and equitable clinical research. The latest guidance: https://lnkd.in/gAbQV4Ek #ClinicalTrials #DiversityInResearch #EquitableTrials #Leapcure #FDA #PatientCentricity #HealthcareInnovation
Crafting tech vision & business goals for growth & innovation
1moThanks for sharing Zachary Gobst. I was having a conversation on equity in clinical trials and AI last week with someone. I'll have to dig into this and learn more.